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Introduction
Hepatitis C virus (HCV) remains a major problem world-
wide, and is responsible for a large number of deaths related 
to HCV-associated hepatocellular carcinoma (HCC) and cir-
rhosis [1]. About 3% of the world’s population, or around 80 
million people, are infected with HCV [2]. While its preva-
lence varies by geographic region, reliable epidemiological 
data are not available [3–5]. In addition, many HCV-infected 
individuals are unaware of being infected, but frequently 
progress to advanced fibrosis, cirrhosis, and HCC [1]. In 
addition to the liver, extra hepatic manifestations of HCV 
infection also cause significant negative impact and a sub-
stantial number of deaths [6, 7].
The availability of direct acting antiviral drugs (DAAs) 
has significantly changed management of HCV by providing 
clinicians with tools to modify the natural history of HCV 
infection, transmission and/or re-infection.
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Background The recent availability of direct acting antivi-
ral drugs (DAAs) has drastically changed hepatitis C virus 
(HCV) treatment scenarios, due to the exceedingly high rates 
of sustained virological response (SVR) and excellent toler-
ability allowing for treatment at all disease stages.
Methods A panel of Italian experts was convened twice, in 
November 2016 and January 2017, to provide further sup-
port on some open issues and provide guidance for personal-
ized HCV care, also in light of forthcoming regimens.
Results and conclusions Treatment recommendations 
issued by international and national liver societies to guide 
clinicians in the management of HCV infection are con-
stantly updated due to accumulating new data. Such recom-
mendations may not be applicable to all healthcare settings 
for a variety of reasons. Moreover, some gaps still remain 
and the spectrum of patients to be treated is also evolving.
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Considering the rapidly accumulating data on the use of 
DAAs, treatment guidelines have been issued by the Ameri-
can (AASLD), European (EASL) and Italian (AISF) liver 
societies to guide clinicians in routine management of HCV 
infection [8–10], even if some gaps remain. With the aim of 
providing further support for clinicians, a panel of Italian 
experts was convened twice in November 2016 and January 
2017, the first via web conference and the second a face-to-
face meeting in Rome, to discuss relevant aspects. Herein, 
the expert’s opinion on some of these open issues has been 
summarized, and relative statements made to provide guid-
ance for clinicians on selected issues in the management of 
HCV infections.
Treatment perspectives with new drugs
In 2016, two novel DAAs combinations, elbasvir/grazo-
previr and sofosbuvir/velpatasvir, have been registered for 
use in USA and Europe. The glecaprevir/pibrentasvir combi-
nation has recently been licensed by EMA and will become 
available by the end of 2017, while the triple combination 
of sofosbuvir/velpatasvir/voxilaprevir has recently been 
approved by the FDA [11]. Still other combinations such as 
elbasvir/ruzasvir/uprifosbuvir are currently under evaluation 
in phase III trials [12]. Of note, at least in Italy, sofosbuvir 
and sofosbuvir/ledipasvir are no longer reimbursed by the 
national healthcare system since May 2017.
The new combination of sofosbuvir/velpatasvir is avail-
able for treatment of genotypes 1, 2, 3, 4, 5 and 6; [13].
The NS3/4A protease inhibitor grazoprevir combined 
with the NS5A inhibitors elbasvir is able to eradicate HCV 
in patients with genotype 1 and 4 [14]. It is now considered 
that this new combination offers an opportunity to cure HCV 
infection with short interferon (IFN)-free therapy, even in 
difficult to treat patients such as those with cirrhosis, HIV 
co-infection, patients with CKD stages 4–5 and/or on dialy-
sis, as well as those who have failed previous therapy [15].
The upcoming pangenotypic combination of glecaprevir/
pibrentasvir can be administered to all patients regardless of 
genotype, allowing treatment for 8 weeks in patients with 
low viral load (< 6 million IU/mL) or in patients without 
cirrhosis and naive to DAAs. Indeed, the results of the phase 
3 study Endurance 1 concluded that 8 weeks of treatment 
are not less effective than 12 weeks in patients with HCV 
genotype 1 even if co-infected with HIV [16]. A regimen of 
12 weeks should be chosen for patients with genotypes 4, 
5, or 6 [17], previous failure to peg-IFN and ribavirin, and 
in experienced or cirrhotic patients with genotype 3 [18].
Patients with mild disease are easiest to treat. In fact, 
even if the new antiviral drugs are much less influenced by 
host parameters, severe disease is associated with lower SVR 
rates on both IFN-containing and IFN-free combination 
regimens. This is related to a slower, second-phase HCV-
RNA decline in cirrhotic vs. non-cirrhotic patients, even 
if the molecular mechanisms underlying the infected cell 
clearance in cirrhotic patients are still unclear. To overcome 
the low rate of viral response, patients with advanced dis-
ease should be treated with long regimens, and ribavirin is 
strongly recommended in some cases [19]. Conversely, in 
patients with mild disease, the efficacy of antiviral treatment 
is higher.
Relevant points
• Elbasvir/grazoprevir can eradicate HCV in most patients 
with genotype 1 and 4, both treatment naïve and treat-
ment experienced, with compensated cirrhosis (Child–
Pugh A) and without cirrhosis.
• Sofosbuvir/velpatasvir is available and effective for 
patients with genotypes 1, 2, 3, 4, 5 and 6.
• Early treatment of comorbidities is needed even in the 
absence of advanced liver disease.
• Patients with advanced liver disease should be treated 
with long regimens, and ribavirin is strongly recom-
mended in some cases.
Pharmacology of new DAAs
Two new STRs have completed their development phase and 
were approved in 2016, namely elbasvir/grazoprevir (NS5A 
inhibitor + NS3/4A inhibitor) and sofosbuvir/velpatasvir 
(NS5B inhibitor + NS5A inhibitor). Glecaprevir/pibrentas-
vir (GCV/PBV, NS3/4A inhibitor + NS5A inhibitor) is at 
the end of its clinical development and in an earlier phase 
of development, there are three DAAs that are classifiable, 
respectively, as a NS5B inhibitor (uprifosbuvir, MK-3682), 
NS3/4 inhibitor (voxilaprevir), and NS5A inhibitor (ruzas-
vir, MK-8408).
Metabolism and drug–drug interactions
Elbasvir/grazoprevir
These drugs are both substrates of the cytochrome P450 
isoenzyme CYP3A4 and membrane transporter P-glyco-
protein (Pgp), making them candidate victims of mol-
ecules acting on CYP3A4 and/or Pgp as inducers (e.g. 
rifampicin, efavirenz) or inhibitors (e.g. anti-HIV boosted 
protease inhibitors), while their potential as perpetrators 
of drug–drug interactions appears to be low, and possi-
bly mediated by BCRP inhibition (both) or weak inhibi-
tion of CYP3A4 (grazoprevir) or Pgp (elbasvir). No sig-
nificant drug–drug interactions have been observed when 
the combination is co-administered with buprenorphine, 
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naloxone, famotidine, pantoprazole, tacrolimus, mycophe-
nolate moetil, prednisone, montelukast, digoxin, or the 
phosphate binder sevelamer. An increase in grazoprevir 
exposure was observed in case of co-administration with 
cyclosporin, while co-administration led to overexposure 
of both atorvastatin and rosuvastatin. Concomitant use of 
a proton pump inhibitor use does not reduce the efficacy of 
elbasvir/grazoprevir. Elbasvir and grazoprevir have elimi-
nation half-lives of 31 and 24 h, respectively, which allows 
for QD administration [20–22].
Velpatasvir
This drug is marketed in co-formulation with the well-estab-
lished NS5B inhibitor sofosbuvir. Velpatasvir is metabolized 
by CYP3A4, CYP2C8, and CYP2B6, and is a substrate of 
the transporters Pgp, BCRP, OAT1B1 and OAT1B3 on 
which it exerts mild inhibitory action [23, 24]. Thus, vel-
patasvir is more a candidate victim of cytochrome P450 
enzymes rather than a relevant perpetrator of drug–drug 
interactions. Expectedly, the pharmacokinetic exposure of 
velpatasvir is reduced in case of co-administration with efa-
virenz, and, vice versa, tends to minor increases in exposure 
when given with a boosted anti-HIV protease inhibitor. The 
solubility of elpatasvir decreases as the pH increases. Thus, 
drugs that increase gastric pH are expected to decrease the 
levels of velpatasvir. Co-administration of omeprazole or 
other proton-pump inhibitors is not recommended. If it is 
considered medically necessary to co-administer a proton-
pump inhibitor, velpatasvir should be taken with food 4 h 
before omeprazole 20 mg. Use with other proton-pump 
inhibitors has not been studied. Velpatasvir was found to 
increase exposure of both rosuvastatin and tenofovir, prob-
ably as a result of transporter inhibition; its elimination half-
life is around 15 h, which is compatible with QD administra-
tion [25].
Glecaprevir/pibrentasvir
A relevant feature of this combination consists of the sig-
nificant increase of pibrentasvir attributable to glecaprevir, 
with a rise in Cmax and Ctrough of almost five- and seven-
fold, respectively [26]. Drug–drug interactions have been 
assessed with some antiretrovirals, resulting in an increase 
in rilpivirine by around twofold (all pharmacokinetic param-
eters) and an increase in the Ctrough of raltegravir by almost 
threefold, with no variations for glecaprevir/pibrentasvir. 
The plasma elimination half-life is around 3 h for glecaprevir 
and 4 h for pibrentasvir, with a subsequent multiexponential 
subsequent phase; QD administration is successful in the 
clinical conditions tested [27].
Uprifosbuvir (MK‑3682), ruzasvir (MK‑8408), voxilaprevir 
(GS‑9857)
Uprifosbuvir has a plasma elimination half-life < 3 h, dose 
proportional pharmacokinetics, and no tendency to accumu-
late. No clinico-pharmacological information is available 
for ruzasvir; voxilaprevir is substrate of both CYP3A4 and 
CYP2C8 as well as substrate and inhibitor of the transport-
ers Pgp, BCRP, and several OATPs. As a perpetrator, vox-
ilaprevir was found to increase the AUC of both rosuvas-
tatin and pravastatin by approximately eight- and twofold, 
respectively, possibly as a result of both BCRP and OAT 
inhibition [11, 23].
Pharmacokinetics in advanced liver disease
As is also seen with first and second generation DAAs, 
NS3/4 inhibitors display an overt tendency to increase 
their pharmacokinetic exposure when a certain degree of 
advanced impairment of liver vasculature and metabolic 
capacity is present. Grazoprevir and glecaprevir show a log 
magnitude of pharmacokinetic exposure increase in decom-
pensated cirrhotic patients, while this is not the case for vel-
patasvir and elbasvir, although the latter is only available in 
combination with grazoprevir. It is thus apparent that NS5A 
inhibitors can be administered in case of decompensated 
cirrhosis, while protease inhibitors are not recommended or 
contraindicated in case of Child–Pugh stage B and C [28].
Relevant points
• Close scrutiny of the pharmacology of the new DAAs is 
warranted due to limited data available.
• NS5A inhibitors can be used in patients with decompen-
sated cirrhosis, while protease inhibitors are not recom-
mended or contraindicated beyond Child–Pugh stage B7.
• PPI use with EBR/GZR has no significant effect on 
SVR12 rates in GT1/4-infected patients with and without 
cirrhosis.
• Co-administration of sofosbuvir/velpatasvir with PPI is 
not recommended.
HCV resistance associated variants: problems 
and solutions
HCV resistance involves both natural and selected resistance 
associated substitutions (RASs). Globally, natural resistance 
to NS5A inhibitors is found with highly variable prevalence 
according to HCV-genotype and geographic region, ranging 
from 13 to 30% [29, 30]. In DAA-naïve patients, resistance 
testing, therefore, can confirm the presence of pre-existent 
NS5As RASs that confer high-level resistance, thus allowing 
 M. Andreoni et al.
1 3
the addition of ribavirin and/or increasing the duration of 
treatment to individualize therapy [19, 31]. At the same 
time, clinicians should be aware that HCV sequencing is 
not only useful to identify RASs, but also to confirm the 
“correct” genotype.
Studies evaluating the effects of natural HCV NS5A 
RASs in response to the combination of ledipasvir and 
sofosbuvir in patients with HCV genotype 1 infection, 
with or without ribavirin, have shown that baseline RASs 
in NS5A-naïve patients have minimal effects on responses 
to ledipasvir/sofosbuvir [32]. However, when these RASs 
do have effects, they can be largely overcome by extending 
treatment duration or through treatment intensification. The 
2016 recommendations of the EASL highlight that treatment 
of NS5A-naïve GT-1a patients can be modulated by the pres-
ence of NS5A RASs.
In HCV genotype 3 NS5A-naive patients treated with vel-
patasvir/sofosbuvir, SVR12 was 84% in patients with natural 
Y93H; moreover, the addition of ribavirin greatly enhances 
the efficacy of the combination, from 50 to 85% [33]. Simi-
larly, the 2016 recommendations of the EASL have provided 
guidance for HCV genotype 3.
HCV resistance to DAAs also plays an important role in 
the failure of IFN-free treatment regimens [31], as limited 
retreatment options are available, and the presence of resist-
ant viral strains may significantly affect their effectiveness 
[34]. For instance, retreatment with 24 weeks of sofosbuvir/
velpatasvir plus weight-based ribavirin led to 97% SVR12 in 
NS5A-xperienced genotype 1 patients and 91% in genotype 
2, while among 13 patients with genotype 3 infection and 
Y93H NS5A-RAS, the SVR12 rate was reduced to 82% [35]. 
In this setting, EASL guidance currently suggests to defer 
HCV treatment for patients without indication for urgent 
retreatment [19]. Otherwise, retreatment strategies should 
be tailored on HCV resistance testing results, in the context 
of 24-week regimens plus [19, 34].
Relevant points
• When needed, retreatment may require ‘unconventional’ 
approaches with multiple DAAs along with genotype 
resistance testing.
• This possibility stresses the need to individualise DAA 
treatment not only before starting therapy, but also most 
importantly after failure.
Role of current and next generation DAA: 
divergence between guidelines
This discussion is based on the recommendations of the 
AASLD, EASL, CIHR, and AISF, which have been updated 
considering the newly approved combinations as first-line 
therapeutic options [8, 19, 36, 37].
Sofosbuvir/velpatasvir
The approved indications in Europe consider ribavirin as 
optional in combination with sofosbuvir and velpatasvir in 
the treatment of genotype 3 in subjects with cirrhosis, differ-
ent from USA and Canada in which treatment for 12 weeks 
without ribavirin is recommended in all subjects with cir-
rhosis and reserving ribavirin only for those with heart 
failure. EASL, AASLD, and AISF recommendations con-
sider the use of sofosbuvir and velpatasvir as optimal for all 
genotypes and all patients regardless of stage of disease and 
presence of hepatic decompensation. For sofosbuvir and vel-
patasvir, there is a recommendation for 12-week administra-
tion without ribavirin in all subjects with compensated liver 
disease and infection with a genotype that is different from 
3, regardless of the stage of disease and previous exposure 
to IFN and ribavirin. For genotype 3, there is a discrepancy 
between the European and US recommendations with regard 
to subjects without cirrhosis and previously treated with IFN 
and ribavirin; all European recommendations require the use 
of ribavirin in combination with velpatasvir for 12 weeks. In 
subjects with cirrhosis, both recommendations suggest the 
use of ribavirin, although both suggest limiting the use of 
ribavirin in subjects with resistance mutations in the NS5A 
region as they affect resistance to velpatasvir.
Elbasvir/grazoprevir
In Europe, the combination is indicated for 12 weeks with-
out ribavirin in genotype 1b. For genotype 1a, the FDA 
suggests a duration of 16-week treatment with ribavirin in 
patients with substitutions associated with resistance in the 
NS5a region, regardless of the level of viremia and stage of 
disease, while the Canadian regulatory authority suggests 
this schedule in patients who have failed a combination of 
IFN and ribavirin with non-negative HCV-RNA during 
treatment and the EMA in patients with viral load greater 
than 800,000 IU/mL and resistance mutations in the NS5A 
region. In the US and AISF recommendations, genotype 4 
treatment is for 12–16 weeks with ribavirin in patients who 
showed any type of failure with a combination of IFN and 
ribavirin, while the Canadian regulations limit this sched-
ule only to those who have not shown negativization of 
viremia during previous therapy with IFN and ribavirin; 
EMA indications reserve this schedule to all subjects with 
baseline viral load > 800,000 IU/mL regardless of response 
to previous IFN and ribavirin. In genotype 1a, US recom-
mendations suggest ribavirin and a duration of 16 weeks of 
therapy in subjects with resistance mutations in the NS5A 
region prior to treatment, making pre-treatment evaluation 
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necessary. The European recommendations are based on 
the heterogeneity of healthcare systems, while taking into 
consideration the availability of resistance testing among 
different countries.
Relevant points
• Despite the absence of firm evidence, it is suggested to 
add ribavirin to sofosbuvir/velpatasvir in patients with 
genotype 3 infection who are unresponsive to treatment 
with peg-IFN and in those with decompensated cirrhosis.
• For individuals who are retreated with currently available 
regimens, tailoring retreatment based on NS5A and NS3 
resistance profile is recommended. In addition, 24-week 
regimens and the association with ribavirin are generally 
indicated.
• With elbasvir/grazoprevir, the suggestion is to treat 
without ribavirin for 12 weeks in all patients with geno-
types 1 and 4, with or without cirrhosis (Child–Pugh 
A), except in those with genotype 1a resistance muta-
tion in the NS5A region at baseline and/or with HCV-
RNA > 800,000 IU/mL and in those with genotype 4 
HCV-RNA > 800,000 IU/mL.
• Treatment with elbasvir/grazoprevir can be considered 
for 8 weeks in naïve subjects with genotype 1b infection 
and fibrosis < 3.
Hepatocellular carcinoma and DAAs: 
a controversial story
The achievement of a SVR to interferon-based therapies has 
been shown to improve the course of hepatitis C in terms of 
reduced rates of liver-related complications and all-cause 
mortality. Hill and co-authors presented 5-year observational 
data of 34,563 patients with and without SVR who had 
been treated with antivirals. Elimination of HCV resulted 
in a decrease of 5-year-mortality by 62–84%; the risk for 
development of HCC was lowered by 68–79%; the risk for 
liver transplantation was lowered by 90% [38]. A post hoc 
analysis of the HALT-C trial confirmed two prior large ret-
rospective follow-up studies from Italy and France in which 
the incidence of HCC among patients with SVR was signifi-
cantly lower compared to those without SVR [39–41]. Mor-
gan et al. [42] described a similar HCC risk reduction with 
SVR among patients with all stages of fibrosis (HR 0.24) 
with a separate analysis, although predominantly including 
studies from Asia where the risk of HCC is substantially 
higher.
Several meta-analyses [43–46] have suggested that IFN 
treatment may prevent HCC recurrence, with conflicting 
data on survival. Miao et al. [43] showed that IFN not only 
reduced late recurrent HCCs but also early ones, especially 
in patients with pure HCV infection. Cabibbo et al. [47] 
recently published a meta-analysis comparing IFN-based 
therapy with no treatment in patients with HCV-related early 
HCC who achieved complete response after surgical resec-
tion or ablation and that did not receive any adjuvant treat-
ment. Pooled estimates of actuarial recurrence rates were 
7.4% at 6 months and 47% at 2 years.
An increased risk of de novo HCC in patients has been 
reported in patients treated with DAAs. Kobayashi et al. [48] 
indicated that the risk of HCC after SVR is similar, indepen-
dently of a DAA or IFN-based regimen.
Reig et al. [49] published the first report of HCC recur-
rence in patients who had achieved SVR following DAAs 
from four Spanish centers. Considering patients who started 
DAA treatment less than 4 months after HCC treatment, 
the HCC recurrence rate was 41.2%. After surgical resec-
tion or RFA, HCC recurrence at 1-year may be expected 
in about 20% of patients [50]. Conti et al. [51] evaluated 
the early occurrence of HCC in 285 cirrhotic patients with-
out history of liver cancer and recurrence of HCC in 59 
cirrhotic patients with a history of previously-treated HCC 
treated with DAAs who achieved SVR. HCC recurred in 
29% of patients treated with either surgical resection, radi-
ofrequency ablation, trans-arterial chemoembolization, or 
percutaneous ethanol injection. De novo HCC occurred in 
3.2% of patients, similar to a historic population of untreated 
cirrhotic patients in which the cumulative occurrence rate 
of HCC was 3.2% at 1 year [50]. A French study on three 
distinct prospective multicenter cohorts including more than 
6000 patients did not report an increased risk of HCC recur-
rence in DAA-treated patients vs. untreated patients [52]. In 
the ANRS CO22 HEPATHER cohort (267 patients previ-
ously treated for HCC of whom 189 received DAA and 78 
did not) and in ANRS CO12 CirVir (79 cirrhotic patients 
who received curative treatment of HCC among whom 13 
received DAA and 66 did not), the rates of HCC recurrence 
did not differ in DAA-treated and untreated patients.
Most recently, Reig and colleagues have reported on 
the recurrence rates of HCC associated in time with DAA 
therapy [53]. Among the 77 patients in the cohort, 31.2% 
had HCC recurrence. Considering those who started HCV 
treatment within 4 months after SVR, the rate of recurrence 
was 45%. Thus, it is possible that the timing of DAA therapy 
in patients undergoing first treatment for HCC may affect 
the recurrence rate, although more studies are needed in this 
regard.
Relevant points
• Sustained HCV clearance by either IFN-based or DAA 
regimens minimizes the rate of progression of HCC to 
cirrhosis and hence indirectly reduces the risk of HCC.
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• The residual risk of HCC after SVR may be due also to 
age, severity of liver disease and comorbidities as the 
rates of HCC recurrence do not differ in DAA-treated 
and untreated patients.
HCV‑related compensated cirrhosis
Treatment in patients with cirrhosis has been difficult due 
to low SVR rates and higher risks of serious adverse events 
compared to those without cirrhosis. DAA-based regimens 
are currently recommended by international guidelines 
as the standard of care for compensated cirrhotic patients 
because of their virological efficacy, ease of use, and toler-
ability [54].
Genotypes 1 and 4
Sofosbuvir/ledipasvir
In treatment-experienced patients with HCV-1 cirrhosis, 
the addition of ribavirin to sofosbuvir/ledipasvir allows for 
shortening treatment to 12 vs. 24 weeks of treatment without 
ribavirin, without compromising SVR [19, 54–60].
Paritaprevir/ritonavir, ombitasvir, and dasabuvir with/
without ribavirin
The US FDA has issued a warning that treatment with rito-
navir-boosted paritaprevir, dasabuvir, and ombitasvir can 
cause serious liver injury in patients with more advanced 
liver disease [19, 54, 61–65]. Moreover, these combinations 
are no longer recommended by the AASLD or EASL [36, 
66].
Sofosbuvir/daclatasvir
At present, 12 weeks of treatment without ribavirin are cur-
rently recommended for treatment-naïve patients with geno-
types 1a, 1b, or 4 as well as in treatment-experienced (DAA-
naive) genotype 1b patients; ribavirin addition or treatment 
prolongation to 24 weeks should be considered in genotype 
1a and genotype 4 treatment-experienced patients [19, 67].
Elbasvir/grazoprevir
Treatment-naïve and treatment-experienced patients 
infected with subtype 1b as well as treatment-naive patients 
infected by genotype 4 should receive this combination for 
12 weeks without ribavirin; treatment should be prolonged 
to 16 weeks with the addition of ribavirin in genotype 1a 
patients with higher viral load (≥ 800,000 IU/mL) or with 
baseline NS5A RASs conferring resistance to elbasvir, as 
well as in genotype 4 treatment-experienced patients with 
higher viral load (≥ 800,000 IU/mL) [14, 19, 54, 68–72]. 
C-SALVAGE examined the use of elbasvir/grazoprevir 
plus R ribavirin BV in patient with chronic HCV genotype 
1 infection (cirrhotic and non-cirrhotic patients) after fail-
ure of peg-IFN and ribavirin [69]. The final results of that 
trial showed that SVR24 was achieved in 96.2% of patients; 
however, baseline resistance-associated variants reappeared 
at relapse in the three patients with virologic failure [68]. 
C-WORTHY also evaluated elbasvir/grazoprevir with or 
without ribavirin in previously untreated patients with cir-
rhosis and patients with previous null response with or with-
out cirrhosis, which reported SVR12 rates ranging from 90 
to 100% [72]. Zeuzem et al. [14] studied elbasvir/grazoprevir 
in cirrhotic and non-cirrhotic treatment-naive patients with 
genotype 1, 4, or 6 infection, reporting SVR12 in 95% of 
cases with similar, high rates across genotypes, and virologic 
failure in only 4% of cases.
Sofosbuvir/velpatasvir
Sofosbuvir/velpatasvir for 12 weeks without ribavirin is 
currently recommended in treatment of HCV-1 and HCV-4 
compensated cirrhotic patients. This recommendation is 
based on the results of the Phase III ASTRAL-1 trial where 
SVR12 was observed in 98% of patients, including 98% in 
those infected with genotype 1a and 99% in those infected 
with genotype 1b [19, 73].
Genotype 2 treatment options
Sofosbuvir/ribavirin
The combination of sofosbuvir plus ribavirin is no longer 
recommended in the most recent European guidelines. 
Nonetheless, in settings where another option is not avail-
able, this combination (or even the combination peg-IFN 
plus ribavirin) remains acceptable based on several studies 
[19, 54, 74–77].
Sofosbuvir/daclatasvir
Daclatasvir is active in  vitro against HCV genotype 2. 
Although limited data are available with this genotype, 
and by analogy with the results obtained with sofosbu-
vir/velpatasvir, the combination of sofosbuvir/daclatasvir 
(12 weeks without ribavirin) appears as a reasonable option 
for patients with genotype 2 infection who are ribavirin-
intolerant [19, 78]. Sofosbuvir and sofosbuvir/ledipasvir 
are no longer reimbursed by the Italian national healthcare 
system since May 2017.
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Sofosbuvir/velpatasvir
The phase III ASTRAL programme evaluating the FDC of 
sofosbuvir and velpatasvir for 12 weeks (without ribavirin) 
reported an SVR12 rate of 100% [13, 19, 54, 73].
Genotype 3 treatment options
Sofosbuvir/peg‑IFN/ribavirin
Although not clearly recommended by latest European 
guidelines, this combination remains a good therapeutic 
option in well compensated HCV-3 patients who are able 
to tolerate a short course of IFN-based therapy. This evi-
dence was clearly pointed out by the BOSON study [79].
Sofosbuvir/daclatasvir
Following the latest European guidelines, both treatment-
naïve and treatment-experienced patients infected with 
HCV genotype 3 with compensated cirrhosis should be 
treated with this combination for 24 weeks with daily 
weight-based ribavirin [19, 54, 80–82]. As already men-
tioned, at least in Italy, sofosbuvir and sofosbuvir/ledipas-
vir are no longer reimbursed by the national healthcare 
system since May 2017.
Sofosbuvir/velpatasvir
This combination is recommended by European guide-
lines with a treatment regimen of 12 weeks with ribavirin 
(mandatory in patients carrying the Y93H NS5A RAS at 
baseline) or 24 weeks without ribavirin (if a reliable test 
for RAS detection is not available at baseline) [13, 19, 54].
No reliable data are currently available on long-term 
follow-up of compensated cirrhotic patients achieving 
SVR by DAAs, as their introduction was too recent to 
infer such conclusions, while conflicting data are emerg-
ing on HCC de-novo onset and/or recurrence after viral 
eradication by DAAs-based therapy.
Relevant points
• While numerous new regimens lead to SVR rates 
never achieved in the past, the increasing recognition 
of difficult to cure subgroups indicates that there is 
still additional work to be done in cirrhotic treatment-
experienced genotype 3 patients and in those who fail 
previous DAA-based regimens carrying RASs that con-
fer resistance to multiple classes of DAAs.
• The continuous need of ribavirin in specific treatment 
regimens remains a critical issue that significantly lim-
its their use in patients who are poorly tolerant or riba-
virin intolerant.
• The next generation of DAAs promises to be pangeno-
typic, with a higher barrier of resistance and ribavarin-
free, overcoming many of these limitations.
HCV infection in special populations
Patients with HCV‑HIV co‑infection
Treatment of HCV-HIV coinfections has been recently 
reviewed elsewhere, noting that drug interactions between 
DAA and medications given those with HIV infection can 
result in treatment failure and adverse events, and response 
to DAAs may be further impaired by viral interference [83]. 
In Europe, there are currently several IFN-free DAA regi-
mens approved for patients with HCV and HIV co-infection. 
All these treatments have high rates of virologic response 
similar to those obtained in patients with HCV infection 
alone. In the era of highly effective antiretroviral therapies, 
HIV response does not seem to be affected by co-infection 
[84] and HCV virologic cure has been shown to reduce the 
risk of liver-related outcomes, including liver decompensa-
tion and mortality [85, 86].
The potential contribution of HCV to HIV disease patho-
genesis still remains poorly understood. Relatively to immu-
nity, patients with HCV co-infection have significantly lower 
CD4 counts and worse CD4 cell recovery after 6 months 
of antiretroviral therapy than HIV mono-infected patients 
[87], and a meta-analysis shows that co-infected patients 
have less immune reconstitution, as determined by CD4 cell 
count after 48 weeks of ART, than do patients with HIV 
infection alone [88]. Moreover, patients successfully treated 
with pegylated-IFN plus ribavirin with 24-month follow-up 
showed a significant annual increase in CD4+ T cells from 
baseline [89]. HCV is associated with increased apoptosis 
of T lymphocytes in HIV-infected patients and this could 
induce a negative impact on CD4+ cell homeostasis, and 
possibly explain the more pronounced decreases in CD4+ 
cell count and reduced CD4+ cell count recovery observed 
during antiretroviral therapy [90]. Despite sustained HIV 
suppression under antiretroviral therapy, HCV co-infection 
supports an expansion of the CD8+ cell compartment, which 
results in a poorer restoration of the CD4+/CD8+ ratio than 
in HIV mono-infected patients [91].
Increased immune activation has been proposed as one 
of the underlying mechanisms of poor clinical outcome 
in HIV/HCV co-infected patients. Co-infected patients 
display a high level of T cell activation and exhaustion 
in the peripheral blood that are correlated with the level 
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of HCV or HIV viremia [92]. Furthermore, activation of 
CD4+ T cells, macrophages, and dendritic cells enhances 
viral replication of HIV and HCV [93, 94], while higher 
HCV and HIV viral loads correlate with increased levels 
of systemic markers of immune activation, faster progres-
sion to AIDS, and cirrhosis [95]. There is general consen-
sus, in successfully treated patients, that HIV replication 
at low copies (< 50 copies/mL) is correlated with the 
persistence of immune activation and disease progression 
[96]. Persistent levels of CD4+ and CD8+ T cell acti-
vation were demonstrated in patients with viremia < 50 
copies/mL who had poor immunological reconstitution 
and in a group of 833 patients, on fully active antiret-
roviral therapy for more than 96 months, HIV residual 
viremia < 50 copies/mL was associated with HCV anti-
body positivity [97].
Furthermore, the extracellular HCV core induces 
secretion of pro-inf lammatory cytokines, including 
TNF-α and IL-6 in antigen-presenting cells [98]. Thus, 
treatment of HCV infection could be followed by a 
reduction of inflammation that may be considered as an 
important strategy for reducing HIV viral replication and 
slowing disease progression. The combination IFN-α plus 
ribavirin has been associated with a significant reduction 
in markers of both T cell activation [99] and endothe-
lial dysfunction [100] in HIV-HCV co-infected patients 
receiving antiretroviral therapy.
Lastly, it has been recently pointed out that men who 
have sex with men (MSM) initiating pre-exposure HIV 
prophylaxis are at risk of HCV infection, and indeed the 
prevalence of HCV among previously HIV-negative MSM 
is higher than expected [101]. This finding has obvious 
implications for HCV testing in MSM at high risk for 
HCV, especially before initiating any prophylaxis for HIV.
Patients with HCV‑HBV co‑infection
Another special population in chronic HCV infection is 
represented by those with chronic HBV. With regards to 
DAAS, there is some evidence to suggest that patients 
with chronic HCV and overt or occult HBV coinfection 
may reactivate HBV when HCV is suppressed or eradi-
cated by DAAs [102]. HBV reactivation has been thought 
to occur earlier in HCV patients coinfected with overt 
and occult HBV who are treated with pan-oral DAAs vs. 
IFN-based treatments [103]. Accordingly, at least dur-
ing therapy with pan-oral DAAs, clinicians should con-
sider screening all patients for evidence of HBV infec-
tion. Anti-HBV therapy with nucleoside analogs should 
be considered if increases in HBV DNA are observed in 
patients with HBV/HCV co-infection [104].
Relevant points
• Curative HCV therapy in HIV co-infected patients is 
associated with better control of HIV replication at low 
copies and with better immune system recovery.
• Due to the known correlation between persistent inflam-
mation and emergence of severe comorbidities in HIV/
HCV co-infected subjects, the available data reinforce 
the importance of treatment for HCV in HIV co-infected 
patients, regardless of the degree of hepatic fibrosis.
• Elbasvir/grazoprevir can be considered in case of impor-
tant drug to drug interactions and renal problems in co-
infected patients.
• Patients with HBV-HCV coinfection should be closely 
monitored for changes in HBV DNA; therapy with 
nucleoside analogs should be considered when appro-
priate although clinical focus should be placed on the 
dominant viral disease (HCV vs. HBV).
HCV infection in people who inject drugs
In the developed world, a large percentage of HCV occurs 
in people who inject drugs (PWID); unfortunately, treat-
ment uptake in this population remains low [105]. In Italy, 
63.9% of PWID are HCV antibody positive, and 68.3% are 
HCV viremic [106]. In Italian jails, which have a very high 
number of PWID (32%), the prevalence of HCV antibod-
ies ranges from 23 to 38% [107, 108]. Outcomes of HCV 
treatments in PWID either actively or with past history of 
drug injection, indicate SVR rates equal to other patients. 
The many problems in managing HCV treatment in these 
patients rarely lead to initiation of therapy [109], even with 
a short DAA regimens. Unfortunately, a high proportion 
of these subjects is unaware of being HCV-positive and, 
as occurs in HIV, present a four- to sixfold higher prob-
ability of transmitting the virus [110]. For these reasons, 
the WHO considers PWID as a target population for HCV 
eradication and relies on two basic elements: grant all HCV 
patients with access to care and eliminate virus transmis-
sion. In PWID, the elbasvir/grazoprevir combination has 
been assessed in the CO-EDGE CO-STAR trial, in which 
injecting drug use was reported by 25% of patients in the last 
6 months, and by 21% of patients in the last month where an 
SVR12 was achieved in 95% of patients [111].
Relevant points
• All patients known as PWID, either actively or with past 
history of injecting should be evaluated for the presence 
of HCV.
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• Screening programs in high risk groups for transmission, 
such as PWID, and extended access to therapy are of 
paramount importance.
• EBR/GZR demonstrated high efficacy in GT1 or 
4-infected patients receiving OAT.
HCV+ patients with chronic kidney disease
In the HCV setting, patients with CKD remain a difficult-to-
treat population even in the era of DAAs, which is related 
to the pharmacological properties of some classes of DAAs 
and the relative lack of data on safety and efficacy of DAAs 
in CKD, due to the strict inclusion/exclusion criteria on esti-
mated glomerular filtration rate (eGFR) that have excluded 
these patients from Phase III RCTs [19]. Patients on hemo-
dialysis and those with kidney transplantation (KT) show a 
high prevalence of HCV infection mainly as a consequence 
of increased risk of nosocomial transmission in dialysis 
facilities. Viral eradication reduces the risk of kidney fail-
ure and improves graft survival in KT patients [112–114]. In 
general, the available data from C-SURFER study imply that 
the grazoprevir/elbasvir combination has good efficacy in 
patients with HCV genotype 1 and CKD stage 4 or 5 includ-
ing those on dialysis, with SVR12 approaching 100% [115].
DAA therapy of HCV patients with CKD
Sofosbuvir‑free combination regimens based on protease 
inhibitors
Paritaprevir/ritonavir/ombitasvir + dasabuvir or elbasvir/
grazoprevir are the only recommended regimens for patients 
with severe CKD (stage 4–5, eGFR < 30 mL/min/1.73 m2) 
[19]. Whereas sofosbuvir together with its circulating metab-
olite GS-331007 is cleared by the kidney, it should be used 
with caution in subjects with severe renal impairment (CKD 
stage 4–5).
Due to the observed changes in pharmacological expo-
sure, this regimen is not recommended in patients with Stage 
4–5 CKD, while elbasvir/grazoprevir as well as the multi-
DAA regimen of paritaprevir/ritonavir/ombitasvir plus dasa-
buvir has been shown to be safe and effective, achieving high 
rates of SVR [116, 117].
At the same time, it is important to underline that ribavi-
rin is necessary in HCV-1a when treating with elbasvir/gra-
zoprevir (in those with NS5A resistance-associated baseline 
polymorphisms at amino acid positions 28, 30, 31 or those 
with a baseline HCV-RNA value > 800,000 IU/mL) or pari-
taprevir/ritonavir/ombitasvir plus dasabuvir (in all cases). 
Since ribavirin is excreted renally and is associated with 
significant adverse effects, mainly anemia, in patients with 
CKD any regimen containing ribavirin should be viewed 
as suboptimal. In addition, these regimens should not be 
prescribed to patients with decompensated cirrhosis due to 
increased serum concentrations of the protease inhibitor, 
which can lead to serious treatment-related adverse events 
and even death [19].
Owing to the lack of non sofosbuvir-based pangenotypic 
regimens, treatment of CKD stage 4–5 patients infected with 
HCV genotypes 2, 3, 5, and 6 remains an unmet clinical 
need, and second-generation PI-based regimens are expected 
to overcome the genotypic barrier of HCV therapy. Very 
limited data exist on sofosbuvir in CKD stage 4–5, as only 
relatively small cohort studies have been reported. The find-
ing that sofosbuvir may impair kidney function has not been 
reported in Phase III studies and has not been highlighted 
in other small cohorts of patients with CKD or KT who 
received sofosbuvir-based regimens [118, 119]. Recently, 
the Phase 3 C-SURFER study has assessed the elbasvir/gra-
zoprevir combination in 224 treatment-naive and treatment-
experienced patients with HCV genotype 1 infection and 
stage 4–5 CKD; SVR12 was 99%, and the combination had 
a low rate of adverse events [116].
In the IFN era, treatment of HCV in KT recipients was 
severely restricted by an increased risk of infectious compli-
cations and graft rejection. A RCT in HCV-1 and 4 infected 
patients with long-term stable KT demonstrated the safety 
and efficacy (100% success rate) of a 12 week ribavirin-free 
regimen based on sofosbuvir/ledipasvir [120]. The favora-
ble outcomes of IFN-free therapy for HCV in KT patients 
have been confirmed by a real-life study where the safety 
of treatment in terms of prevention of graft rejection was 
optimal in patients who started therapy at least 3 months 
after transplantation [121].
Relevant points
• Elbasvir/grazoprevir or Paritaprevir/ritonavir/ombitas-
vir + dasabuvir are the only recommended regimens 
for patients with Stage 4-5 CKD. However new KDIGO 
Guidelines recommend for HCV genotype 1 subtype 
A and subtype B the use of elbasvir/grazoprevir with 
a grade of recommendation 1A. (KDIGO 2017 clinical 
practice guideline on the prevention, diagnosis, evalua-
tion and treatment of hepatitis C in CKD).
• In patients with CKD any regimen containing ribavirin 
should be viewed as suboptimal.
• IFN-free therapy for HCV in KT patients appear effec-
tive, but need further study.
HCV+ patients with inherited blood disorders
A significant number of subjects with inherited blood dis-
orders (IBLD), including those with hemoglobinopathies 
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such as sickle cell disease and thalassemia or clotting fac-
tor deficiencies such as haemophilia and von Willebrand, 
have chronic HCV and many develop chronic liver disease. 
HCV infection is a main risk factor for development of liver 
damage, and increases steadily with longer duration of HCV 
infection.
Data for new regimens with DAAs in patients with IBLD 
are limited to a small number of studies. The first assessed 
the sofosbuvir/ledipasvir combination associated with rib-
avirin in 14 patients with HCV genotype 1 and inherited 
bleeding disorders (11 hemophilia, 2 von Willebrand dis-
ease, 1 factor XIII deficiency) [122]. All patients achieved 
a SVR after 12 weeks of follow-up. A cohort study [123] 
evaluated 12 weeks of sofosbuvir/ledipasvir in 43 Japanese 
hemophilia patients with genotype 1 or 4. 20 patients had 
HIV co-infection. SVR 12 was 90% in HIV-positive patients 
and 100% in HIV-negative patients. The rate of SVR in the 
patients with cirrhosis was significantly lower than that in 
non-cirrhosis patients (p = 0.005). Overall, 46% of patients 
had adverse events; most were mild to moderate, although 
3 were serious including 1 death in the HIV-positive group.
Finally, a randomized, placebo-controlled, phase 3 trial 
assessed the safety and efficacy of elbasvir/grazoprevir 
administered for 12 weeks (159 adults with HCV infection 
and sickle cell anemia, thalassemia, or haemophilia A/B or 
von Willebrand disease) with inherited bleeding disorders 
and HCV infection [124]. Patients were randomized into a 
group that immediately received the drug or to a deferred-
treatment group that received placebo followed by active 
treatment. In the former, 93.5% achieved SVR12 and no dif-
ferences between pathologies were seen.
Relevant points
• Clinical data on new regimens with DAAs in patients 
with IBLD are limited, but appear to indicate that these 
new regimes are effective with an acceptable safety pro-
file.
• Elbasvir/grazoprevir regimen has been studied also in 
patients with inherited bleeding disorders and HCV 
infection.
Extrahepatic manifestations of HCV: mixed 
cryoglobulinemia
Mixed cryoglobulinemia (MC) is the most frequent and 
largely investigated extrahepatic manifestation of HCV 
[125–127]; while it is clinically benign, it can be associated 
with severe symptoms and possibly evolve into lymphoma 
[128, 129]. In a cohort of 231 MC patients, 79 of 97 deaths 
were linked to vasculitis (46%, of which one-third due to 
renal involvement), cancer or hemopathy (23%), or liver 
disease (13%) [130].
In the “IFN era”, antiviral treatment of MC followed the 
evolution of HCV treatment with small adjustments (i.e. in 
drug dose/duration, combination with non-antiviral thera-
pies), essentially due to the possible side-effects of IFN 
and/or ribavirin therapy. Clinical remission correlated with 
virological response, although discordant data have been 
reported [131–134]. The rare persistence of MC after viral 
eradication obtained by different regimens may be due to 
several causes [135].
The introduction of first-generation DAAs in combination 
with peg-IFN and ribavirin was associated with increased 
SVR rates above historical levels, but with increased side-
effects. Peg-IFN plus ribavirin plus boceprevir or telaprevir 
administered to 30 MC patients resulted in 67% of complete 
clinical and virological response, while 47% of patients had 
severe side effects [136]. Another study confirmed the good 
efficacy of this combination in 22 MC patients, and cryoglo-
bulinemia resolution in 86% of cases, but a lower SVR rate 
in cryoglobulinemic patients than in patients without MC 
(23.8 vs 70%, p = 0.01) [137]. In a small case series of MC 
patients treated with peg-IFN plus ribavirin plus sofosbu-
vir or first generation DAAs, longer treatment for cirrhotic 
patients was suggested [138, 139].
The available data suggest that IFN-free regimens are 
safe, generally well-tolerated, and effective in MC patients 
[140–143]. In the IFN era, rituximab was administered 
mostly to patients who had failed or were not eligible for 
antiviral therapy, even if a rituximab plus antiviral combina-
tion was suggested for patients with severe manifestations 
(generally using rituximab before antiviral therapy) [132, 
144–146]. With the introduction of DAAs, a role for rituxi-
mab remains to be established.
Antiviral therapy should be considered as the first-line 
approach in HCV-associated low grade lymphomas if there 
is no urgency of conventional treatment, irrespective of liver 
damage [147–150].
Relevant points
• First-generation DAAs in combination with peg-IFN and 
ribavirin have increased SVR rates over historical levels, 
while more data is needed on the safety profile in patients 
with MC.
• The available data suggest that IFN-free regimens 
are safe, generally well tolerated, and effective in MC 
patients.
• Antiviral therapy should be considered as the first-line 
approach in HCV-associated low-grade lymphomas if 
there is no urgency for conventional treatment, indepen-
dently of liver damage.
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Quality of life in HCV+ patients and role of cure
Chronic HCV infection is associated with a number of 
extrahepatic manifestations that may significantly affect 
the patient’s health-related quality of life (HRQOL) [151]. 
Impairment in HRQOL in patients with chronic HCV infec-
tion is mainly driven by fatigue, insomnia, anxiety, and 
depression which are prevalent comorbid conditions, and 
may also affect adherence to antiviral treatment [152].
It is well known that in patients treated with peg-IFN 
and ribavirin show a decrease in both physical and men-
tal component summary scores at the end of treatment (all 
p < 0.05), which reverts at the end of follow-up [153]. In 
general, by curing HCV, patient-reported outcomes (PROs) 
return to values similar to a healthy population. These 
findings are in line with the observation of patient-related 
assessments following treatment with sofosbuvir/ledipasvir 
with and without ribavirin [154]. Patients receiving this regi-
men showed significant improvement of PROs that coincide 
with early viral suppression after 2 weeks of treatment and 
maximized by the end of treatment. This finding provides 
support for the hypothesis that HCV itself is responsible 
for a significant component of HRQOL impairment; conse-
quently, early viral suppression is followed by improvement 
in PROs.
The double-blind placebo-controlled study ASTRAL-1 
is of particular importance in defining the role of viral sup-
pression in improvement of PROs [155]. Patients receiving 
placebo did not experience any HRQOL improvement, and 
only those in the active regimen of sofosbuvir/velpatasvir 
had improvement in PROs. Multivariate analysis also indi-
cated that HCV clearance was a strong predictor in improv-
ing PROsduring post-treatment follow-up. Also in ASTRAL, 
almost all patient-reported dimensions were significantly 
more affected in decompensated versus compensated and 
versus non-cirrhotic patients. The only three dimensions that 
were impaired to a similar degree in the three groups were 
mental health, mental component summary of SF-36, and 
social wellbeing of FACIT-F. This implies that the mental 
dimensions of HRQOL are not affected by physical condi-
tions per se, but that they are under a direct influence of 
viral infection, which affects the mental well-being areas 
across the board regardless of the degree of severity of the 
concomitant liver disease.
Fatigue and other psychological comorbidities are rel-
evant issue in chronic HCV patients. In 19% of HCV 
patients, clinically severe fatigue, both central and periph-
eral is observed, and anxiety, depression, and insomnia are 
reported in 23–26% of patients [156]. During treatment, 
ribavirin administration was associated with fatigue and psy-
chiatric distress. However, 4 weeks after treatment, fatigue 
was reported to improve in all patients, and in ribavirin-free 
regimens peripheral fatigue showed a greater improvement.
Relevant points
• Ribavirin administration delays improvement in patient-
reported outcomes potentially due to viral eradication, 
and is frequently followed by substantial improvement 
of all HRQOL domains.
• After achievement of SVR, significant improvement of 
patient-reported outcomes is observed regardless of the 
regimen employed.
• The breadth of improvement in patient-reported out-
comes is higher in decompensated than in compensated 
cirrhosis, which supports the use of antiviral therapy at 
any stage of liver disease.
Conclusions
The availability of all new DAA regimens for treatment 
of HCV infection will dramatically change management 
approaches in routine practice. In general, the new DAAs 
are highly effective, well-tolerated and enable clinicians to 
an ever increasing number of patients. The newest DAA 
regimes, and especially elbasvir/grazoprevir and sofosbu-
vir/velpatasvir, are also changing routine management of 
chronic HCV infection in many patients with comorbidi-
ties, in addition to cirrhosis. In special populations, the 
new DAAs are also finding clinical utility, such as in those 
with HIV co-infection and in those who inject drugs, and 
are associated with high rates of sustained viral clearance. 
Patients with renal impairment are also another significant 
subpopulation of subject with chronic HCV infection. It is 
clear that HCV infection is associated with diminished qual-
ity of life considering a wide range of domains. As such, 
sustained viral clearance will improve patients’ HRQOL, 
and as such achieving this should be a major clinical goal. 
Thus, antiviral therapy is warranted at any stage of liver 
disease or in the presence of other comorbidities to improve 
patients’ overall well-being.
While international guidelines have been published to 
help clinicians in the management of patient with HCV 
infection, such recommendations may not be applicable to 
all healthcare settings for a variety of reasons. The present 
expert recommendations have aimed to bridge some of the 
remaining clinical gaps regarding the use of new DAAs, 
while keeping in mind the highly encouraging results that 
have been achieved to date with these regimens in patients 
with a range of comorbidities.
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